View Item 

Show simple item record

Antiâ viral therapy is associated with improved survival but is underutilised in patients with hepatitis B virusâ related hepatocellular carcinoma: realâ world east and west experience
dc.contributor.authorChen, V. L.
dc.contributor.authorYeh, M.‐l.
dc.contributor.authorLe, A. K.
dc.contributor.authorJun, M.
dc.contributor.authorSaeed, W. K.
dc.contributor.authorYang, J. D.
dc.contributor.authorHuang, C.‐f.
dc.contributor.authorLee, H. Y.
dc.contributor.authorTsai, P.‐c.
dc.contributor.authorLee, M.‐h.
dc.contributor.authorGiama, N.
dc.contributor.authorKim, N. G.
dc.contributor.authorNguyen, P. P.
dc.contributor.authorDang, H.
dc.contributor.authorAli, H. A.
dc.contributor.authorZhang, N.
dc.contributor.authorHuang, J.‐f.
dc.contributor.authorDai, C.‐y.
dc.contributor.authorChuang, W.‐l.
dc.contributor.authorRoberts, L. R.
dc.contributor.authorJun, D. W.
dc.contributor.authorLim, Y.‐s.
dc.contributor.authorYu, M.‐l.
dc.contributor.authorNguyen, M. h.
dc.date.accessioned2018-06-11T18:00:09Z
dc.date.available2019-09-04T20:15:38Zen
dc.date.issued2018-07
dc.identifier.citationChen, V. L.; Yeh, M.‐l. ; Le, A. K.; Jun, M.; Saeed, W. K.; Yang, J. D.; Huang, C.‐f. ; Lee, H. Y.; Tsai, P.‐c. ; Lee, M.‐h. ; Giama, N.; Kim, N. G.; Nguyen, P. P.; Dang, H.; Ali, H. A.; Zhang, N.; Huang, J.‐f. ; Dai, C.‐y. ; Chuang, W.‐l. ; Roberts, L. R.; Jun, D. W.; Lim, Y.‐s. ; Yu, M.‐l. ; Nguyen, M. h. (2018). "Antiâ viral therapy is associated with improved survival but is underutilised in patients with hepatitis B virusâ related hepatocellular carcinoma: realâ world east and west experience." Alimentary Pharmacology & Therapeutics 48(1): 44-54.
dc.identifier.issn0269-2813
dc.identifier.issn1365-2036
dc.identifier.urihttps://hdl.handle.net/2027.42/144277
dc.publisherWiley Periodicals, Inc.
dc.publisherAmerican Cancer Society
dc.titleAntiâ viral therapy is associated with improved survival but is underutilised in patients with hepatitis B virusâ related hepatocellular carcinoma: realâ world east and west experience
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelPharmacy and Pharmacology
dc.subject.hlbsecondlevelOtolaryngology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/144277/1/apt14801_am.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/144277/2/apt14801.pdf
dc.identifier.doi10.1111/apt.14801
dc.identifier.sourceAlimentary Pharmacology & Therapeutics
dc.identifier.citedreferenceMinistry of Health and Welfare. Details of the application criteria and methods of medical treatment benefits. http://www.mohw.go.kr/react/jb/sjb0406vw.jsp?PAR_MENU_ID=03&MENU_ID=030406&CONT_SEQ=342581&page=1. Accessed March 26, 2018
dc.identifier.citedreferenceLai CL, Yuen MF. Prevention of hepatitis B virusâ related hepatocellular carcinoma with antiviral therapy. Hepatology. 2013; 57: 399 â 408.
dc.identifier.citedreferenceLiaw Yâ F, Sung JJY, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004; 351: 1521 â 1531.
dc.identifier.citedreferenceCoffin CS, Rezaeeaval M, Pang JX, et al. The incidence of hepatocellular carcinoma is reduced in patients with chronic hepatitis B on longâ term nucleos(t)ide analogue therapy. Aliment Pharmacol Ther. 2014; 40: 1262 â 1269.
dc.identifier.citedreferenceChong CCN, Wong GLH, Wong VWS, et al. Antiviral therapy improves postâ hepatectomy survival in patients with hepatitis B virusâ related hepatocellular carcinoma: a prospectiveâ retrospective study. Aliment Pharmacol Ther. 2015; 41: 199 â 208.
dc.identifier.citedreferenceYin J, Li N, Han Y, et al. Effect of antiviral treatment with nucleotide/nucleoside analogs on postoperative prognosis of hepatitis B virusâ related hepatocellular carcinoma: a twoâ stage longitudinal clinical study. J Clin Oncol. 2013; 31: 3647 â 3655.
dc.identifier.citedreferenceWong JS, Wong GL, Tsoi KK, et al. Metaâ analysis: the efficacy of antiâ viral therapy in prevention of recurrence after curative treatment of chronic hepatitis Bâ related hepatocellular carcinoma. Aliment Pharmacol Ther. 2011; 33: 1104 â 1112.
dc.identifier.citedreferenceWu Câ Y, Chen Yâ J, Ho HJ, et al. Association between nucleoside analogues and risk of hepatitis B virusâ related hepatocellular carcinoma recurrence following liver resection. J Amer Med Assoc. 2012; 308: 1906.
dc.identifier.citedreferenceLee TY, Lin JT, Zeng YS, Chen YJ, Wu MS, Wu CY. Association between nucleos(t)ide analog and tumor recurrence in hepatitis B virusâ related hepatocellular carcinoma after radiofrequency ablation. Hepatology. 2016; 63: 1517 â 1527.
dc.identifier.citedreferenceXu X, Huang P, Tian H, et al. Role of lamivudine with transarterial chemoembolization in the survival of patients with hepatocellular carcinoma. J Gastroenterol Hepatol. 2014; 29: 1273 â 1278.
dc.identifier.citedreferenceXu L, Gao H, Huang J, et al. Antiviral therapy in the improvement of survival of patients with hepatitis B virusâ related hepatocellular carcinoma treated with sorafenib. J Gastroenterol Hepatol. 2015; 30: 1032 â 1039.
dc.identifier.citedreferenceYang Y, Wen F, Li J, et al. A high baseline HBV load and antiviral therapy affect the survival of patients with advanced HBVâ related HCC treated with sorafenib. Liver Int. 2015; 35: 2147 â 2154.
dc.identifier.citedreferenceTerrault NA, Bzowej NH, Chang KM, et al. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016; 63: 261 â 283.
dc.identifier.citedreferenceLiaw YF, Kao JH, Piratvisuth T, et al. Asianâ Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int. 2012; 6: 531 â 561.
dc.identifier.citedreferenceEuropean Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017; 67: 370 â 398.
dc.identifier.citedreferenceLim SG, Amarapurkar DN, Chan HL, et al. Reimbursement policies in the Asiaâ Pacific for chronic hepatitis B. Hepatol Int. 2015; 9: 43 â 51.
dc.identifier.citedreferenceLiou IW, Nguyen MH. The cascade of care in chronic hepatitis B. Curr Hepatol Rep. 2016; 15: 209 â 219.
dc.identifier.citedreferenceKu KC, Li J, Ha NB, Martin M, Nguyen VG, Nguyen MH. Chronic hepatitis B management based on standard guidelines in community primary care and specialty clinics. Dig Dis Sci. 2013; 58: 3626 â 3633.
dc.identifier.citedreferenceKim LH, Nguyen VG, Trinh HN, Li J, Zhang JQ, Nguyen MH. Low treatment rates in patients meeting guideline criteria in diverse practice settings. Dig Dis Sci. 2014; 59: 2091 â 2099.
dc.identifier.citedreferenceBruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011; 53: 1020 â 1022.
dc.identifier.citedreferencePark JW, Chen M, Colombo M, et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. Liver Int. 2015; 35: 2155 â 2166.
dc.identifier.citedreferenceNational Center for Health Statistics. National Death Index. https://www.cdc.gov/nchs/ndi/index.htm. Accessed March 26, 2018.
dc.identifier.citedreferenceSarin SK, Kumar M, Lau GK, et al. Asianâ Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016; 10: 1 â 98.
dc.identifier.citedreferenceNational Health Insurance Administration. Drug reimbursement regulations. https://www.nhi.gov.tw/Content_List.aspx?n=E70D4F1BD029DC37&topn=3FC7D09599D25979. Accessed March 26, 2018
dc.identifier.citedreferenceDuffy SW, Nagtegaal ID, Wallis M, et al. Correcting for lead time and length bias in estimating the effect of screen detection on cancer survival. Am Journal Epidemiol. 2008; 168: 98 â 104.
dc.identifier.citedreferenceThein Hâ H, Campitelli MA, Yeung LT, Zaheen A, Yoshida EM, Earle CC. Improved survival in patients with viral hepatitisâ induced hepatocellular carcinoma undergoing recommended abdominal ultrasound surveillance in Ontario: a populationâ based retrospective cohort study. PLoS ONE. 2015; 10: e0138907.
dc.identifier.citedreferenceLlovet JM, Real MI, Montaña X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. The Lancet. 2002; 359: 1734 â 1739.
dc.identifier.citedreferenceLlovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359: 378 â 390.
dc.identifier.citedreferenceLin D, Yang HI, Nguyen N, et al. Reduction of chronic hepatitis Bâ related hepatocellular carcinoma with antiâ viral therapy, including low risk patients. Aliment Pharmacol Ther. 2016; 44: 846 â 855.
dc.identifier.citedreferenceLok AS, McMahon BJ, Brown RS Jr, et al. Antiviral therapy for chronic hepatitis B viral infection in adults: a systematic review and metaâ analysis. Hepatology. 2016; 63: 284 â 306.
dc.identifier.citedreferenceTong MJ, Hsien C, Hsu L, Sun HE, Blatt LM. Treatment recommendations for chronic hepatitis B: an evaluation of current guidelines based on a natural history study in the United States. Hepatology. 2008; 48: 1070 â 1078.
dc.identifier.citedreferenceChen TM, Chang CC, Huang PT, Wen CF, Lin CC. Performance of risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACHâ B) score in classifying treatment eligibility under 2012 Asian Pacific Association for the Study of the Liver (APASL) guideline for chronic hepatitis B patients. Aliment Pharmacol Ther. 2013; 37: 243 â 251.
dc.identifier.citedreferenceKumar M, Kumar R, Hissar SS, et al. Risk factors analysis for hepatocellular carcinoma in patients with and without cirrhosis: a caseâ control study of 213 hepatocellular carcinoma patients from India. J Gastroenterol Hepatol. 2007; 22: 1104 â 1111.
dc.identifier.citedreferenceKwak HW, Park JW, Nam BH, et al. Clinical outcomes of a cohort series of patients with hepatocellular carcinoma in a hepatitis B virusâ endemic area. J Gastroenterol Hepatol. 2014; 29: 820 â 829.
dc.identifier.citedreferenceChen CH, Su WW, Yang SS, et al. Longâ term trends and geographic variations in the survival of patients with hepatocellular carcinoma: analysis of 11,312 patients in Taiwan. J Gastroenterol Hepatol. 2006; 21: 1561 â 1566.
dc.identifier.citedreferenceChen VL, Le AK, Kim NG, et al. Effects of cirrhosis on shortâ term and longâ term survival of patients with hepatitis Bâ related hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2016; 14: 887 â 895. e1.
dc.identifier.citedreferenceYang JD, Kim WR, Coelho R, et al. Cirrhosis is present in most patients with hepatitis B and hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2011; 9: 64 â 70.
dc.identifier.citedreferenceChayanupatkul M, Omino R, Mittal S, et al. Hepatocellular carcinoma in the absence of cirrhosis in patients with chronic hepatitis B virus infection. J Hepatol. 2017; 66: 355 â 362.
dc.identifier.citedreferenceAmerican Cancer Society. Global Cancer Facts & Figures. Atlanta: American Cancer Society; 2011.
dc.identifier.citedreferenceBeasley RP, Lin Câ C, Hwang Lâ Y, Chien Câ S. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan. Lancet. 1981; 2: 1129 â 1133.
dc.identifier.citedreferencePoon RT, Fan ST, Lo CM, Liu CL, Ng IO, Wong J. Longâ term prognosis after resection of hepatocellular carcinoma associated with hepatitis Bâ related cirrhosis. J Clin Oncol. 2000; 18: 1094 â 1101.
dc.identifier.citedreferenceKim JM, Kwon CH, Joh JW, et al. Differences between hepatocellular carcinoma and hepatitis B virus infection in patients with and without cirrhosis. Ann Surg Oncol. 2014; 21: 458 â 465.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
apt14801_am.pdf
Size:
294.4KB
Format:
PDF
View/Open
Name:
apt14801.pdf
Size:
809.8KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.